European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
October 31, 2023
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that its primary creditor, the European Investment Bank (EIB), is currently considering favorably adjusting the […]
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the publication today of its financial results for the third quarter ended Sept. 30, 2023 and […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023
October 30, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6–8, 2023, in Munich, Germany. According […]
Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
October 30, 2023
Showcasing Scinai’s end-to-end cGMP Biologics CDMO services at booth 271 Pursuing partnerships for Scinai’s pipeline of novel VHH antibody-based therapies JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces that it will be showcasing both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH […]
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event
October 27, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that brings together pharmaceutical professionals, industry leaders, and businesses to advance human health. The event is scheduled for October 24 to […]
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Promising Results in Its Pursuit of Safe, Effective Treatments for Large, Underserved Population of Plaque Psoriasis Patients
October 23, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical and biotechnology company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological therapeutics, recently announced encouraging results from a preclinical study that suggest the therapeutic potential of the anti-interleukin 17 (“IL-17”) nanosized antibodies (“NanoAbs”) to relieve symptoms of plaque psoriasis (https://ibn.fm/mFsNO). Plaque psoriasis is the most […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at CPHI Barcelona 2023, Other Upcoming Events
October 4, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI) today announced that it will showcase its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place Oct. 24 to 26. Scinai’s CDMO offers upstream and downstream process development and scale-up for protein-based drugs, analytical method development, and cGMP manufacturing including aseptic filling to biopharmaceutical […]
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development
October 4, 2023
Biopharmaceutical company Scinai Immunotherapeutics (NASDAQ: SCNI) recently raised $1.33 million in gross proceeds from its previously announced registered direct offering of 1,146,522 of its American Depositary Shares (“ADSs”) (or ADS equivalents), which closed September 19. Moreover, in a concurrent private placement, the company issued unregistered warrants to purchase up to 1,146,522 ADSs representing ordinary shares. […]
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
October 4, 2023
JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) — via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place October 24 to 26. Several members of Scinai’s executive leadership team will be available to meet with potential […]
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification
October 2, 2023
When Amir Reichman took over the reins as CEO of the then-named BiondVax Pharmaceuticals in March 2021, he and the Board of Directors embarked on redefining the biotechnology company’s mission and vision. “Our new mission reflects an aspiration to focus on infectious diseases, which leverages [the company’s] core competencies, while ensuring fdiversification of our corporate […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.33M Registered Direct Offering
September 20, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company’s American Depositary Shares (“ADSs”). According to the announcement, each ADS represented four hundred ordinary shares […]
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
September 20, 2023
JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) — via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces $1.33M Registered Direct
September 15, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. The company today announced its entry into a definitive agreement for the purchase and sale of 1,146,552 of the company’s American Depositary Shares (“ADSs”) (or […]
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
September 15, 2023
JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) — via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that it has entered into a definitive agreement for the purchase and sale of 1,146,552 of […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Plaque Psoriasis Treatment Study
September 14, 2023
Scinai Immunotherapeutics(NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting encouraging results from its preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis. According to the report, study results suggest […]
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
September 14, 2023
Scinai’s NanoAbs downregulated key molecular markers overexpressed in plaque psoriasis Stratum corneum regained normal appearance in laboratory 3D skin model Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024 JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) — via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company […]
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee
September 12, 2023
Psoriasis is a chronic disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. According to the National Psoriasis Foundation, 125 million people worldwide have psoriasis. Nearly 50% of people with psoriasis experience moderate to severe symptoms (https://ibn.fm/jgqwh). The psoriasis treatment market was valued at $16.45 billion in 2022 and […]
InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation in H.C. Wainwright, LSX USA Congress 2023 and Upcoming Conferences
September 11, 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., today announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and the LSX USA Congress 2023 in […]
Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
September 11, 2023
JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) — via IBN — Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., announced today that CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and […]
InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Rebrands as Scinai Immunotherapeutics Ltd.
September 6, 2023
BiondVax (NASDAQ: BVXV), a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into […]
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
September 6, 2023
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) — via IBN — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai”). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion […]